NeoDynamics: Reaches important milestone in US
NeoDynamics reaches important milestone in US - First order received.
In less than a year from FDA approval, NeoDynamics receive their first order in US from a prominent US university hospital specializing in the treatment of breast cancer. However modest in size, the order will serve as an important reference as the commercial rollout continues to garner interest and acceptance at both academic and community based breast centers throughout the U.S.
Read full announcement here: US order
In case you missed our latest event with management in connection with Q2 - listen here: Q2 interview
Disclaimer:
HC Andersen Capital receives payment from NeoDynamics for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 09:30 AM 10-08-2023.
